SCHEMBL719017

SCHEMBL719017

COc1cccc2cc(C(Cl)C3CCCCC3)oc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
HPGD P15428 4/20 0.51
KDM4E B2RXH2 4/20 0.51
RAB9A P51151 4/20 0.51
KMT2A Q03164 4/20 0.51
NPC1 O15118 3/20 0.51
HSD17B10 Q99714 3/20 0.51
MEN1 O00255 3/20 0.51
PKM P14618 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
ADORA2A P29274 2/20 0.50
ADORA2B P29275 1/20 0.50
ADORA1 P30542 1/20 0.48
HTT P42858 1/20 0.46
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720494 0.84 ADORA2A (0.53) ALDH1A1SMN1; SMN2HPGDKDM4ERAB9A
SCHEMBL7421148 0.77 LMNA (0.47) ALDH1A1SMN1; SMN2HPGDKDM4ERAB9A
SCHEMBL7425866 0.77 LMNA (0.50) ALDH1A1SMN1; SMN2HPGDKDM4ERAB9A
SCHEMBL25062632 0.77 CYP2A6 (0.57) ALDH1A1SMN1; SMN2KDM4ERAB9AKMT2A
SCHEMBL21788603 0.74 KMT2A (0.55) ALDH1A1SMN1; SMN2KDM4ERAB9AKMT2A
SCHEMBL29793869 0.74 KMT2A (0.55) ALDH1A1SMN1; SMN2KDM4ERAB9AKMT2A
SCHEMBL717947 0.73 RAB9A (0.44) ALDH1A1SMN1; SMN2HPGDKDM4ERAB9A
SCHEMBL719410 0.72 KDM4E (0.47) ALDH1A1HPGDKDM4ERAB9AKMT2A
SCHEMBL28792307 0.70 SLC6A2 (0.53) ALDH1A1SMN1; SMN2HPGDKDM4ERAB9A
SCHEMBL29876774 0.70 SLC6A2 (0.53) ALDH1A1SMN1; SMN2HPGDKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885SMN1; SMN2 1051/4885HPGD 486/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885SMN1; SMN2 1051/4885HPGD 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.